# Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder

> **NCT01428661** · PHASE2,PHASE3 · COMPLETED · sponsor: **Vanda Pharmaceuticals** · enrollment: 507 (actual)

## Conditions studied

- Major Depressive Disorder

## Interventions

- **DRUG:** tasimelteon
- **DRUG:** placebo

## Key facts

- **NCT ID:** NCT01428661
- **Lead sponsor:** Vanda Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2,PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-09
- **Primary completion:** 2013-01
- **Final completion:** 2013-05
- **Target enrollment:** 507 (ACTUAL)
- **Last updated:** 2015-06-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01428661

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01428661, "Melatonin Agonist Effects of Tasimelteon Versus Placebo in Patients With Major Depressive Disorder". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT01428661. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*